BR0111464A - Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética - Google Patents

Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética

Info

Publication number
BR0111464A
BR0111464A BR0111464-6A BR0111464A BR0111464A BR 0111464 A BR0111464 A BR 0111464A BR 0111464 A BR0111464 A BR 0111464A BR 0111464 A BR0111464 A BR 0111464A
Authority
BR
Brazil
Prior art keywords
diabetic nephropathy
patient
pharmaceutical composition
dosage form
unit dosage
Prior art date
Application number
BR0111464-6A
Other languages
English (en)
Inventor
Ernesto Palazzini
Giovanni Gambaro
Original Assignee
Alfa Wassermann Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Inc filed Critical Alfa Wassermann Inc
Publication of BR0111464A publication Critical patent/BR0111464A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA NA FORMA DE DOSAGEM UNITáRIA, E, MéTODO DE TRATAMENTO DE UM PACIENTE COM NEFROPATIA DIABéTICA". A presente invenção proporciona formulações orais de Sulodexida para o tratamento de nefropatia diabética em pacientes com diabetes melitus tanto dependente de insulina quanto não dependente de insulina. São proporcionadas formulações orais contendo doses adaptadas para administração para obter uma redução na excreção de albumina em pacientes tanto com microalbuminúria quanto com macroalbuminúria e para produzir melhoria duradoura na taxa de excreção de albumina.
BR0111464-6A 2000-06-07 2001-06-06 Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética BR0111464A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20990700P 2000-06-07 2000-06-07
PCT/US2001/018411 WO2001093850A2 (en) 2000-06-07 2001-06-06 Methods and compositions using sulodexide for the treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
BR0111464A true BR0111464A (pt) 2003-05-06

Family

ID=22780806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111464-6A BR0111464A (pt) 2000-06-07 2001-06-06 Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética

Country Status (21)

Country Link
US (2) US7259152B2 (pt)
EP (1) EP1292315B1 (pt)
JP (1) JP2003535129A (pt)
KR (1) KR100815287B1 (pt)
AT (1) ATE409042T1 (pt)
AU (2) AU2001265388B2 (pt)
BR (1) BR0111464A (pt)
CA (1) CA2411243A1 (pt)
CY (1) CY1108595T1 (pt)
DE (1) DE60135911D1 (pt)
DK (1) DK1292315T3 (pt)
ES (1) ES2309070T3 (pt)
HU (1) HUP0301408A2 (pt)
IL (2) IL153074A0 (pt)
MX (1) MXPA02011708A (pt)
NO (1) NO20025849D0 (pt)
NZ (1) NZ522963A (pt)
PL (1) PL201658B1 (pt)
PT (1) PT1292315E (pt)
RU (1) RU2003100081A (pt)
WO (1) WO2001093850A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100417A2 (en) * 2001-06-12 2002-12-19 Keryx Biopharmaceuticals Inc. Use of glycosaminoglycans for the treatment of hiv-associated nephropathy
AU2006244446A1 (en) * 2005-05-05 2006-11-16 Keryx Biopharmaceuticals, Inc. Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
EP1968561B8 (en) * 2005-12-22 2010-10-20 Kiacta Sàrl Treatment of diabetic nephropathy
CN101730529A (zh) * 2006-12-22 2010-06-09 贝鲁斯健康(国际)有限公司 用于治疗代谢疾病和糖尿病的方法、化合物和组合物
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
FR3071283B1 (fr) * 2017-09-21 2022-07-29 Fineheart Pompe cardiaque equipee d'une turbine a pales internes

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2426586A1 (de) 1973-06-14 1975-01-09 Opocrin Srl Verfahren zur herstellung von glukuronil-glukosamin-glykan-sulfaten mit antilipaemischer wirkung
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IT1163772B (it) 1983-07-13 1987-04-08 Baldacci Lab Spa Oligosaccaridi eterogenei complessabili ed alfa-idosani ad attivita' terapeutica, procedimento per la loro preparazione e relative composizioni farmaceutiche
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5413645A (en) 1986-04-25 1995-05-09 Weirton Steel Corporation Light-cage composite-coated flat-rolled steel manufacture and product
US5672334A (en) 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
IT1234508B (it) 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5272261A (en) 1989-01-11 1993-12-21 Merrell Dow Pharmaceuticals Inc. Preparation of sulfated polysaccharide fractions
IT1234826B (it) 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5378829A (en) 1990-04-23 1995-01-03 Akzo N.V. Sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
ATE148713T1 (de) 1990-07-24 1997-02-15 Seikagaku Kogyo Co Ltd Glykosaminoglykan gemischt mit phospholipid oder lipid, seine herstellung und krebszellenmetastaseninhibitor
US5073643A (en) 1990-08-30 1991-12-17 Polyset Corporation High yield synthesis of hydroxyl-containing cationic photoinitiators
IT1242604B (it) 1990-11-13 1994-05-16 Alfa Wassermann Spa Sali di glicosaminoglicani con esteri di aminoacidi, loro preparazione e formulazioni farmaceutiche che li contengono.
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1260137B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2 dell'acido alfa-l-iduronico-2-0-solfato
IT1260136B (it) 1992-04-17 1996-03-28 Alfa Wassermann Spa Glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonicosostituito con radicali nucleofili in posizione 3
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1264102B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici contenenti acido alfa-l-galatturonico sostituito con radicali
IT1264101B1 (it) 1993-03-29 1996-09-10 Alfa Wassermann Spa Processo per la sintesi di glicosaminoglicani semisintetici a struttura eparinica od eparanica modificati nella posizione 2
IT1270846B (it) 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
US5585361A (en) 1994-06-07 1996-12-17 Genzyme Corporation Methods for the inhibition of platelet adherence and aggregation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
IT1299969B1 (it) 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
AU4325499A (en) 1998-06-01 1999-12-20 University Of Maryland Biotechnology Institute Receptor ligand antagonist complexes and their use in treating or preventing receptor mediated diseases
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases

Also Published As

Publication number Publication date
CY1108595T1 (el) 2014-04-09
IL153074A0 (en) 2003-06-24
PL359346A1 (en) 2004-08-23
US20020065233A1 (en) 2002-05-30
CA2411243A1 (en) 2001-12-13
ATE409042T1 (de) 2008-10-15
PT1292315E (pt) 2008-10-16
NZ522963A (en) 2004-11-26
US20080045476A1 (en) 2008-02-21
MXPA02011708A (es) 2004-05-17
WO2001093850B1 (en) 2003-02-20
DK1292315T3 (da) 2008-11-17
US7259152B2 (en) 2007-08-21
NO20025849L (no) 2002-12-05
EP1292315B1 (en) 2008-09-24
ES2309070T3 (es) 2008-12-16
IL153074A (en) 2008-07-08
HUP0301408A2 (hu) 2003-11-28
JP2003535129A (ja) 2003-11-25
AU6538801A (en) 2001-12-17
PL201658B1 (pl) 2009-04-30
KR100815287B1 (ko) 2008-03-19
KR20030031493A (ko) 2003-04-21
EP1292315A2 (en) 2003-03-19
DE60135911D1 (de) 2008-11-06
AU2001265388B2 (en) 2006-12-14
WO2001093850A2 (en) 2001-12-13
NO20025849D0 (no) 2002-12-05
WO2001093850A3 (en) 2002-08-22
RU2003100081A (ru) 2004-07-20

Similar Documents

Publication Publication Date Title
SG149814A1 (en) Compositions and methods for treating diabetes
BRPI0406499A (pt) Insulina de longa atuação para redução da morbidez e mortalidade cardiovascular em pacientes pré-diabéticos e pacientes com diabetes tipo 2
BR0015295A (pt) Formulação e método antidiabético
BR9906813A (pt) Método para administração de insulina aspb28- humana
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
WO2007066149A3 (en) Topical pharmaceutical compositions
BR9907866A (pt) Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR012995A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de medicamentos y composiciones farmaceuticas que contienedichos compuestos.
PT1001802E (pt) Preparacao farmaceutica combinada compreendendo a hormona da paratiroide e um inibidor de reabsorcao ossea
BR0111464A (pt) Composição farmacêutica na forma de dosagem unitária, e, método de tratamento de um paciente com nefropatia diabética
BR0115390A (pt) Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
ATE290858T1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BRPI0409387B8 (pt) complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
DE69910600D1 (de) Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
CA2664300A1 (en) Agent for preventing onset of post-stroke reflex sympathetic dystrophy

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]